PMC:5400020 / 20519-21287 JSONTXT

{"project":"0_colil","denotations":[{"id":"28175264-26384006-6832","span":{"begin":56,"end":57},"obj":"26384006"},{"id":"28175264-27283408-6833","span":{"begin":218,"end":220},"obj":"27283408"},{"id":"28175264-25669644-6834","span":{"begin":491,"end":493},"obj":"25669644"},{"id":"28175264-26198875-6835","span":{"begin":718,"end":719},"obj":"26198875"}],"text":"Though the majority of cases are transfemoral nowadays [2], the transapical approach is still relevant. When transfemoral access is not possible, it is the access of choice, as reported in a recently conducted survey [19]. It has not only the advantage of a short distance to the annulus, resulting in precise control of the device, but also avoids crossing of the aortic arch, which is especially helpful in severely calcified anatomy, and can ultimately be applied in almost all patients [10]. Furthermore, there is a development towards devices with smaller transapical delivery systems. Recently, the combination of ACURATE neoTM with a 22F outer diameter transapical delivery system has been successfully tested [4] and a CE approval trial is currently enrolling."}

{"project":"2_test","denotations":[{"id":"28175264-26384006-28904998","span":{"begin":56,"end":57},"obj":"26384006"},{"id":"28175264-27283408-28904999","span":{"begin":218,"end":220},"obj":"27283408"},{"id":"28175264-25669644-28905000","span":{"begin":491,"end":493},"obj":"25669644"},{"id":"28175264-26198875-28905001","span":{"begin":718,"end":719},"obj":"26198875"}],"text":"Though the majority of cases are transfemoral nowadays [2], the transapical approach is still relevant. When transfemoral access is not possible, it is the access of choice, as reported in a recently conducted survey [19]. It has not only the advantage of a short distance to the annulus, resulting in precise control of the device, but also avoids crossing of the aortic arch, which is especially helpful in severely calcified anatomy, and can ultimately be applied in almost all patients [10]. Furthermore, there is a development towards devices with smaller transapical delivery systems. Recently, the combination of ACURATE neoTM with a 22F outer diameter transapical delivery system has been successfully tested [4] and a CE approval trial is currently enrolling."}

{"project":"MyTest","denotations":[{"id":"28175264-26384006-28904998","span":{"begin":56,"end":57},"obj":"26384006"},{"id":"28175264-27283408-28904999","span":{"begin":218,"end":220},"obj":"27283408"},{"id":"28175264-25669644-28905000","span":{"begin":491,"end":493},"obj":"25669644"},{"id":"28175264-26198875-28905001","span":{"begin":718,"end":719},"obj":"26198875"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Though the majority of cases are transfemoral nowadays [2], the transapical approach is still relevant. When transfemoral access is not possible, it is the access of choice, as reported in a recently conducted survey [19]. It has not only the advantage of a short distance to the annulus, resulting in precise control of the device, but also avoids crossing of the aortic arch, which is especially helpful in severely calcified anatomy, and can ultimately be applied in almost all patients [10]. Furthermore, there is a development towards devices with smaller transapical delivery systems. Recently, the combination of ACURATE neoTM with a 22F outer diameter transapical delivery system has been successfully tested [4] and a CE approval trial is currently enrolling."}

{"project":"testtesttest","denotations":[{"id":"T125","span":{"begin":280,"end":287},"obj":"Body_part"},{"id":"T126","span":{"begin":365,"end":376},"obj":"Body_part"},{"id":"T128","span":{"begin":582,"end":589},"obj":"Body_part"},{"id":"T129","span":{"begin":681,"end":687},"obj":"Body_part"}],"attributes":[{"id":"A125","pred":"uberon_id","subj":"T125","obj":"http://purl.obolibrary.org/obo/UBERON_3010058"},{"id":"A126","pred":"uberon_id","subj":"T126","obj":"http://purl.obolibrary.org/obo/UBERON_0001508"},{"id":"A127","pred":"uberon_id","subj":"T126","obj":"http://purl.obolibrary.org/obo/UBERON_0004363"},{"id":"A128","pred":"uberon_id","subj":"T128","obj":"http://purl.obolibrary.org/obo/UBERON_0000467"},{"id":"A129","pred":"uberon_id","subj":"T129","obj":"http://purl.obolibrary.org/obo/UBERON_0000467"}],"text":"Though the majority of cases are transfemoral nowadays [2], the transapical approach is still relevant. When transfemoral access is not possible, it is the access of choice, as reported in a recently conducted survey [19]. It has not only the advantage of a short distance to the annulus, resulting in precise control of the device, but also avoids crossing of the aortic arch, which is especially helpful in severely calcified anatomy, and can ultimately be applied in almost all patients [10]. Furthermore, there is a development towards devices with smaller transapical delivery systems. Recently, the combination of ACURATE neoTM with a 22F outer diameter transapical delivery system has been successfully tested [4] and a CE approval trial is currently enrolling."}